Vanda Pharmaceuticals (Vanda Pharmaceuticals) Total Inventories : $1.4 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Total Inventories?

Vanda Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $1.4 Mil. Vanda Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $1.2 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Vanda Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $5.41.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Vanda Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 31.16.

Inventory Turnover measures how fast the company turns over its inventory within a year. Vanda Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 2.93.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Vanda Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.03.

Vanda Pharmaceuticals Total Inventories Historical Data

The historical data trend for Vanda Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Total Inventories Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

1.14

1.28

1.03

1.19

1.36

Vanda Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															1.19	1.11	1.08	1.01	1.36

Vanda Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Vanda Pharmaceuticals (NAS:VNDA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Vanda Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(388.264	+	0.75 * 34.155	+	0.5 * 1.357	-	103.53
-	0	-	0)	/	57.5345
=	5.41

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Vanda Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	1.1815	/	3.46	*	365 / 4
	=	31.16

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Vanda Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	3.46	/	1.1815
	=	2.93

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Vanda Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.1815	/	45.271
	=	0.03

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Vanda Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

VM4:Germany VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Executives

Joakim Wijkstrom	officer: SVP, Chief Marketing Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran	officer: VP, Acting CFO & Treasurer	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams	officer: SVP & General Counsel	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos	director, officer: Chief Executive Officer	9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks	officer: SVP, Business Development	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins	director	1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones	officer: Chief Corp. Affairs Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos	director	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan	director	20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly	officer: SVP, CFO, Treasurer & Secretar	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi	officer: SVP, General Manager Europe	2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341